Sherbet Eric
Known title: See RemarksCIK: 0001679512
Associated companies
Transaction History
| IQV | ▼ Sell | Open Market | 5,000 | $1.2M | 7/29/2026 | View on chart |
| IQV | ▲ Buy | Grant | 6,806 | $0 | 2/8/2026 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 1,915 | $359K | 2/8/2026 | View on chart |
| IQV | ▲ Buy | Option Exercise | 10,000 | $1.3M | 10/29/2025 | View on chart |
| IQV | ▼ Sell | Open Market | 4,000 | $879K | 10/29/2025 | View on chart |
| IQV | ▼ Sell | Other | 6,000 | $1.3M | 10/29/2025 | View on chart |
| IQV | ▲ Buy | Option Exercise | 11,870 | $1.2M | 7/23/2025 | View on chart |
| IQV | ▼ Sell | Open Market | 5,800 | $1.1M | 7/23/2025 | View on chart |
| IQV | ▼ Sell | Other | 6,070 | $1.2M | 7/23/2025 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 179 | $37K | 2/10/2025 | View on chart |
| IQV | ▲ Buy | Grant | 2,356 | $0 | 1/28/2025 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 605 | $123K | 1/28/2025 | View on chart |
| IQV | ▼ Sell | Open Market | 1,300 | $320K | 8/27/2024 | View on chart |
| IQV | ▼ Sell | Open Market | 1,000 | $242K | 2/16/2024 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 289 | $63K | 2/10/2024 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 281 | $61K | 2/9/2024 | View on chart |
| IQV | ▲ Buy | Grant | 7,725 | $0 | 2/6/2024 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 2,372 | $511K | 2/6/2024 | View on chart |
| IQV | ▼ Sell | Open Market | 1,000 | $230K | 2/14/2023 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 326 | $73K | 2/10/2023 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 317 | $73K | 2/9/2023 | View on chart |
| IQV | ▲ Buy | Grant | 8,745 | $0 | 2/7/2023 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 3,267 | $770K | 2/7/2023 | View on chart |
| IQV | ▲ Buy | Grant | 2,200 | $0 | 2/10/2022 | View on chart |
| IQV | ▼ Sell | Tax Withholding | 3,788 | $968K | 2/9/2022 | View on chart |
| IQV | ▲ Buy | Grant | 9,114 | $0 | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
IQVIA Expands Veeva Partnership and Raises Price Targets
IQVIA announced an expanded partnership with Veeva Systems to use clinical operations software across its development studies. This move coincides with reports of an improving demand environment and high win rates. Stifel recently raised its price target for the stock to $303, reflecting confidence in the company's backlog and operational updates.
IQVIA Expands Veeva Partnership and Raises Price Targets. IQVIA announced an expanded partnership with Veeva Systems to use clinical operations software across its development studies. This move coincides with reports of an improving demand environment and high win rates. Stifel recently raised its price target for the stock to $303, reflecting confidence in the company's backlog and operational updates.